Data from The <i>EGFR</i> T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor

Abstract

<div>Abstract<p>Molecular target therapies using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be effective for patients with non-small cell lung cancer (NSCLC) who harbor activating mutations in EGFR. However, these patients eventually develop resistance to the reversible TKIs, and this has led to the development of second-generation, irreversible EGFR inhibitors. Currently, the mechanism of acquired resistance to irreversible EGFR inhibitors is not clear. Using an <i>in vitro</i> cell culture system, we modeled the acquired resistance to first-line treatment with second-generation EGFR-TKIs using an <i>EGFR</i>-mutant NSCLC cell line. Here, we report a mechanism of resistance involving T790M secondary mutation as well as a corresponding clinical case. The results of these findings suggest that inhibition of EGFR by currently available second-generation EGFR-TKIs may not be sufficient to physiologically prevent the emergence of cells that are still dependent on EGFR signaling. This finding bears important implications on the limitations of currently available second-generation EGFR-TKIs. <i>Mol Cancer Ther; 11(3); 784–91. ©2012 AACR</i>.</p></div>